Evidence map›Paper›PMID 40574629›Full record

ReviewPathologica2025

Clinical needs and pathology's answers in neuroendocrine neoplasms of the lung.

Giuseppe Pelosi, Alice Laffi, Mauro Papotti, Sylvie Lantuejoul, Jean-Yves Scoazec, Maria Gemelli, Riccardo Ricotta, Sergio Harari, Eleonora Duregon, Riccardo Papa and 7 more

Abstract readReview
In one paragraph

Review in Pathologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Giuseppe Pelosi *Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Alice Laffi *Medical Oncology and Hematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Rozzano, Italy.
Mauro PapottiDepartment of Oncology, University of Turin, Turin, Italy.
Sylvie LantuejoulGrenoble Alpes University, Department of Biopathology, Centre Léon Bérard & Pathology Research Platform, Cancer Research Center of Lyon, Lyon, France.
Jean-Yves ScoazecDepartment of Pathology, Gustave Roussy Cancer Campus, Villejuif, France, Université Paris Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, Villejuif, France.
Maria GemelliMedical Oncology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy.
Riccardo RicottaMedical Oncology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy.
Sergio HarariDepartment of Medical Sciences and Community Health, University of Milan, Milan, Italy.
Eleonora DuregonDepartment of Oncology, University of Turin, Turin, Italy.
Riccardo PapaInter-Hospital Pathology Division, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy.
Angelica SonzogniDepartment of Diagnostic Pathology and Laboratory, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy.
Fabrizio BianchiCancer Biomarker Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
Antonino BrunoInnate Immunity Laboratory, Unit of Molecular Pathology, Biochemistry and Immunology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy.
Barbara BassaniInnate Immunity Laboratory, Unit of Molecular Pathology, Biochemistry and Immunology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy.
Silvia UccellaDepartment of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy.
Carlo CarnaghiOncology and Hematology Unit, Humanitas Istituto Clinico Catanese, Misterbianco (CT), Italy.
Alexia Francesca BertuzziMedical Oncology and Hematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Rozzano, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung neuroendocrine neoplasms (NENs) make up a variegated ensemble of malignancies encompassing typical carcinoid (TC) and atypical carcinoid (AC). These are low to intermediate grade neuroendocrine tumors (NETs), and large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC), which are full-fledged high-grade neuroendocrine carcinomas (NECs) showing similar clinical outcomes. Through a peer interaction between oncologist and pathologist, we herein constructed a practical approach based on questioning and answering regarding 8 practical issues aimed to provide shared solutions for clinical decision-making. These issues were itemized as sequential steps guided by clinical reasoning and concerned differential diagnosis, combined subtypes, primary and metastatic tumors, small diagnostic material, predictive biomarkers, tumor staging and, lastly, standardizing terminology. This study takes advantage of the close interaction between oncologists and pathologists as a tool to better delineate the decision-making on lung NENs.

Indexed as

Carcinoma, NeuroendocrineLung NeoplasmsNeuroendocrine TumorsBiomarkers, TumorCarcinoid TumorClinical Decision-MakingDiagnosis, DifferentialHumansNeoplasm StagingBiomarkers, Tumordiagnosislungneuroendocrine neoplasmsoncologypathology

Identifiers

PMID40574629
PMCPMC12236144

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.